Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.
Europe's most valuable company and the main driver of the Danish economy said it expected its 2024 full-year sales to be up by 23% to 27% from a year earlier, revising its earlier forecast of 22% to 28%.
It cited in a statement "the expectation of continued volume growth and capacity limitations at some manufacturing sites."
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.